Mode
Text Size
Log in / Sign up
Early Phase 1 N=21 Randomized Triple-blind Treatment

New Tool to Enhance Post-stroke Upper Extremity Disability

Stroke

Enrolled (actual)
21
Serious AEs
0.0%
Results posted
Jun 2025
Primary outcome: Primary: Change in Action Research Arm Test (ARAT) Total Score From Baseline to Post-Intervention — 0.72; 0 Units on a scale

Study Design & Population

Study type
Interventional
Phase
Early Phase 1
Interventions
START - Startle Adjuvant Rehabilitation Therapy (Other); Sham Control (Other)
Age
Adult, Older Adult · 18+ yrs
Sex
All
Sponsor
Arizona State University
Primary completion
Dec 2023

Outcome Measures

OutcomeResultp-value
PRIMARY
Change in Action Research Arm Test (ARAT) Total Score From Baseline to Post-Intervention
0.72; 0
PRIMARY
Retention in Action Research Arm Test (ARAT)
1; -0.666667
PRIMARY
Change in Motor Activity Log (MAL) Amount of Use Score From Baseline to Post-Intervention
-2.045455; 0.388889
PRIMARY
Retention in Motor Activity Log (MAL)
5.0625; 12.75
SECONDARY
Change in Upper Extremity Fugl Meyer (UEFM) Baseline to Post-intervention
0.090909; 1.555556
SECONDARY
Retention of Upper Extremity Fugl Meyer From End Training to One-month Post
-0.5; -0.333333
SECONDARY
Change in Stroke Impact Scale From Baseline to Post-intervention
0.363636; -0.777778
SECONDARY
Retention of Stroke Impact Scale - Post-training to One-month Post
-1.375; 2.5

Summary

Individuals with low socioeconomic status (SES) are more likely to have a stroke, more disabled at 3 months, and less likely to be independently ambulatory. Individuals with low SES struggle to adhere to physician guidelines because of 1) increased disability leaves patients ineligible or unable to tolerate therapy, and 2) poor access to quality care i.e., lack of transportation to therapy. To reduce post-stroke disparity in low SES groups, society must invest in development of novel tools that make therapy more accessible. For the past 5 years, the PI has been developing Startle Adjuvant Rehabilitation Therapy (START), a tele-enabled, low-cost treatment to improve upper-extremity therapy outcomes in individuals with stroke - in particular individuals with severe-to-moderate stroke. START is the application of a startling, acoustic stimulus (via headphones) which increases the intensity of practice, particularly in severe patient populations. START is adjuvant, meaning it does not replace clinical practice but instead enhances current evidence-based treatments. Objective: the investigators seek to determine if START can be used to enhance functionally relevant movement of the upper extremity. Preliminary data: Individuals with severe-to-moderate disability from a stroke completed a remotely delivered, 3-day training of object manipulation with START. Box and Blocks, which was targeted during training, demonstrated a large increase under START (+47.1%) compared to Control (+3.3%). Modified functional reach was also increased under START (+8.9%) compared to Control (+1.1%). Impairment also decreased under START (Upper-Extremity-Fugl-Meyer: +8.6%) resulting in subject-reported increase in arm function both in quantity (Motor Activity Log: +26.2%) and quality (+20.2%). These results indicate that START can be deployed remotely and may prove a valuable, adjuvant tool to enhance functional upper extremity movement. The investigators propose to perform a Phase 1 clinical trial on a larger cohort of 58 subjects, with a longer, 5-day training with the goal of establishing that START can 1) enhance functional movement of the upper extremity and 2) generate sustainable changes that impact quality of life. Impact: This proposal is significant because it tests a tool that has the potential to directly target the causes leading to disparity of care for individuals with low SES. A third (34%) of 6.5 million people in the U.S. with stroke are on Medicaid or uninsured. Our best evidence-based therapies (e.g., high-intensity, CIMT) and our emerging rehabilitation technologies (e.g., TMS, robotics) are inaccessible to our minority and low SES populations. START addresses disparity because it 1) targets individuals with severe disability, which disproportionally affects low SES and minority groups, and 2) is tele-enabled eliminating transportation which 60% of individuals with low SES report as a barrier to care. If successful, this study will set the stage for larger trials to establish 1) the effectiveness of START to be incorporated into traditional therapy and as well as patient compliance, adherence, and tolerance - particularly in low SES groups.

Eligibility Criteria

Inclusion Criteria

  • >18 years old
  • Capacity to provide informed consent
  • Cerebral stroke at least 6 months prior to testing
  • Presence of upper extremity impairment associated with stroke
  • Corrected pure tone threshold (octave frequencies 250- 4000 Hz) norms for their age and gender27,28 NOTE: Audiometry data will be collected for all participants by lab personnel trained by an audiologist in a sound-attenuated booth. We expect that ~30% of participants will use hearing aids; we will not exclude these individuals but rather include hearing aid use as a covariate in analyses.

Exclusion Criteria

  • Severe concurrent medical problems (e.g. uncontrolled cardiorespiratory impairment)
  • Acute/painful condition/injury of upper extremity/spine that interfere with ability to participate.
View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT05277389). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.

Back to search